NASDAQ · Health care

Organogenesis Holdings Inc. (ORGO)

Organogenesis Holdings Inc. brought in $457.5M of revenue over the twelve months to June 30, 2026, up 6.5% from a year earlier. It posted a net loss of $84.2M. In fiscal 2025 capital spending exceeded operating cash flow by $24.5M. At June 30, 2026 it held $46.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Price

$1.41

-0.70% on the day · September 25, 2026

52-week range $1.34 to $7.08

Market cap

$181.4M

Revenue (last 12 months)

$457.5M

+6.5% year on year

Net margin

-18.4%

P/E

9.4

on FY2025 diluted EPS

What Organogenesis Holdings Inc. does

Organogenesis Holdings Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ORGO.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$564.2M	$44.7M	$37M	$0.15	-$24.5M
2024	$482M	-$1.3M	$861K	-$0.01	$4.2M
2023	$433.1M	$12.5M	$4.9M	$0.04	$6.6M
2022	$450.9M	$22.3M	$15.5M	$0.12	-$9M
2021	$467.4M	$72.2M	$94.2M	$0.70	$30.8M
2020	$338.3M	$26.7M	$17.2M	$0.15	-$12.2M

Latest SEC filings

What Organogenesis Holdings Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 6, 2026
Material agreement 8-K
August 6, 2026
Securities offering prospectus 424B5
August 6, 2026
Quarterly report 10-Q · period to June 30, 2026
August 6, 2026
Quarterly results 8-K
June 16, 2026
Executive or director change 8-K
May 7, 2026
Quarterly report 10-Q · period to March 31, 2026
May 7, 2026
Quarterly results 8-K
April 30, 2026
Annual report to shareholders ARS
April 30, 2026
Proxy statement DEF 14A
February 26, 2026
Annual report 10-K · period to December 31, 2025

Recent insider filings (Forms 3, 4 and 144): 10, the latest on April 24, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about ORGO

What does Organogenesis Holdings Inc. do?

Organogenesis Holdings Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ORGO.

Is Organogenesis Holdings Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $84.2M on revenue of $457.5M.

How much revenue does Organogenesis Holdings Inc. make?

Over the twelve months to June 30, 2026 Organogenesis Holdings Inc. reported revenue of $457.5M. That is 6.5% more than a year earlier.

When did Organogenesis Holdings Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026.

Similar companies

Follow ORGO

Get an email when Organogenesis Holdings Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ORGO: get an email when it files

Where the numbers come from

Financial figures are the values Organogenesis Holdings Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.